3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
275
Carcinoma, Intraductal, Noninfiltrating
25
Breast Carcinoma In Situ
21
Breast Neoplasms, Male
12
Neoplasm Metastasis
10
Neoplasms
7
Inflammatory Breast Neoplasms
7
Breast Cancer Female
4
Obesity
3
Endometrial Neoplasms
3
Carcinoma, Ductal, Breast
3
Breast Diseases
3
Sleep Wake Disorders
2
Hot Flashes
2
ER+ Breast Cancer
2
Carcinoma, Lobular
2
Vitamin D Deficiency
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Risk Reduction Behavior
1
Recurrence
1
Pulmonary Fibrosis
1
Primary Breast Cancer
1
Premenopausal Breast Cancer
1
Precancerous Conditions
1
Patient Acceptance of Health Care
1
Paget's Disease, Mammary
1
Ovarian Neoplasms
1
Interventions
Fulvestrant
10
Letrozole
4
Alpelisib
4
ribociclib
3
palbociclib
3
Paclitaxel
2
NVP-BKM120
2
volagidemab
1
serabelisib
1
sapanisertib
1
olaparib
1
liposomal doxorubicin
1
gedatolisib
1
exemestane
1
dapagliflozin
1
capivasertib
1
abemaciclib
1
Taxes
1
Tamoxifen
1
Secretin
1
STX-478
1
Metformin
1
Lomustine
1
Leuprolide
1
Irinotecan
1
Imlunestrant
1
Goserelin
1
Gemcitabine
1
Drug Therapy
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
Tamoxifen
×
Breast
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled